MedTrace Logo

Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human

NCT07379177 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-01-30

No results posted yet for this study

Summary

Main objective:

Through blood drug concentration testing, evaluate the post-meal pharmacokinetic characteristics of the curcumin product compared to similar products, and assess the differences in body exposure between the self-developed product and the control product in healthy trial participants.

Secondary objective:

Observe the safety of the self-developed product and the control product in healthy trial participants.

Study population:

Healthy male individuals or non-pregnant non-lactating females

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Curcumin

In the first cycle, take 4 capsules of the self-developed product (T, Nano Curcumin Capsules) (125 mg per capsule), in the second cycle take 2 capsules of the control product (R, Curcumin Capsules) (250 mg per capsule), take with 240 mL of water, and the cleansing period is 7 days.

DIETARY_SUPPLEMENT

Nanocurcumin

In the first cycle, take 2 capsules (250mg each) of the control product (R, Curcumin Capsules). In the second cycle, take 4 capsules (125mg each) of the self-developed product (T, Nano Curcumin Capsules). Take with 240 mL of water and the cleansing period is 7 days.

Sponsors & Collaborators

  • Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-28
Primary Completion
2026-02-07
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07379177 on ClinicalTrials.gov